Literature DB >> 6721467

Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing.

D K Sommers, M Van Wyk, P E Williams, S M Harding.   

Abstract

A total of 158 volunteers each received 21 repeated oral doses of 500 mg of cefuroxime axetil (CAE) during four comparative cross-over trials. Pharmacokinetics were studied in 8 volunteers (CAE versus ampicillin), relative bioavailability and tolerance were studied in 100 volunteers (CAE versus pivmecillinam and CAE versus pivampicillin), and tolerance alone was studied in 50 volunteers (CAE versus ampicillin). Overall, urinary recoveries of the active antibiotics ranked absorption of the drugs in the order least to greatest: pivmecillinam, ampicillin, CAE, and pivampicillin. The pharmacokinetics of CAE and ampicillin did not change after repeated dosing. Peak serum levels of cefuroxime were significantly higher than those of ampicillin after doses 1 and 21 but the urinary recoveries of both antibiotics were around 35% of the dose. CAE was as well tolerated as ampicillin but there were smaller numbers of episodes of fluid bowel motions on pivmecillinam and pivampicillin than on CAE, which may have been due to the smaller amounts of active antibiotic in the doses of the pivaloyloxymethyl esters.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721467      PMCID: PMC185514          DOI: 10.1128/AAC.25.3.344

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  SODIUM AMPICILLIN: ABSORPTION AND EXCRETION OF INTRAMUSCULAR AND INTRAVENOUS DOSES IN NORMAL YOUNG MEN.

Authors:  T C EICKHOFF; J W KISLAK; M FINLAND
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

2.  Absorption and excretion of "Penbritin".

Authors:  E T KNUDSEN; G N ROLINSON; S STEVENS
Journal:  Br Med J       Date:  1961-07-22

3.  Triple crossover study on absorption and excretion of ampicillin, pivampicillin, and amoxycillin.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

4.  Pharmacokinetic studies with mecillinam and pivmecillinam.

Authors:  K Roholt
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

5.  Trimethoprim and rifampicin: pharmacokinetic studies in man.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

6.  Anti-anaerobic antibacterial agents.

Authors:  J G Bartlett
Journal:  Lancet       Date:  1982-08-28       Impact factor: 79.321

Review 7.  Common adverse effects of antibacterial agents on major organ systems.

Authors:  S B Calderwood; R C Moellering
Journal:  Surg Clin North Am       Date:  1980-02       Impact factor: 2.741

8.  Pharmacokinetics of oral cephalosporins: cephradine cephalexin.

Authors:  E Finkelstein; R Quintiliani; R Lee; A Bracci; C H Nightingale
Journal:  J Pharm Sci       Date:  1978-10       Impact factor: 3.534

9.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

10.  Bioavailability and metabolism of talampicillin.

Authors:  K H Jones; P F Langley; L J Lees
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

  10 in total
  13 in total

Review 1.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 2.  Pharmacokinetics and tissue concentrations of cefuroxime.

Authors:  T B Vree; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

3.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Comparative clinical efficacy of single oral doses of cefuroxime axetil and amoxicillin in uncomplicated gonococcal infections.

Authors:  I W Fong; W Linton; M Simbul; N A Hinton
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

5.  Comparative trial of cefuroxime axetil in recurrent urinary tract infections illustrating importance of 6-week follow-up.

Authors:  W Brumfitt; J M Hamilton-Miller; G W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Stereoselective absorption and hydrolysis of cefuroxime axetil diastereomers using the Caco-2 cell monolayer model.

Authors:  M A Barrett; M J Lawrence; A J Hutt; A B Lansley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  Pharmacokinetics of cefuroxime axetil suspension in infants and children.

Authors:  D A Powell; N C James; M J Ossi; M C Nahata; K H Donn
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections.

Authors:  C Brambilla; S Kastanakis; S Knight; K Cunningham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

10.  Pharmacokinetics and bactericidal activity of cefuroxime axetil.

Authors:  C M Ginsburg; G H McCracken; M Petruska; K Olson
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.